Albany, NY -- (SBWIRE) -- 12/31/2015 -- Transparency Market Research's report, titled 'Nonalcoholic Steatohepatitis (NASH) Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015–2023,' offers actionable insights into the market using data-backed analysis. The report states that the NASH market is currently at a nascent stage given the absence of U.S. FDA-approved drugs for the disease currently on the market. However, the market is expected to grow steadily over the coming years as a number of potential drug candidates for NASH are currently in the pipeline at Phase II and III. Aramchol and Elafibranorare among the pipeline drugs, the report notes.

The NASH market will also benefit from the fact that healthcare authorities are now concerned about mitigating the larger impact NASH. This concern stems from the probability of NASH patients' condition progressing into cirrhosis – these patients also stand a greater risk of developing HCC or hepatocellular cancer, as per information published by the American Liver Foundation. With this becoming a concern, more efforts are expected to be deployed for treating the disease.

Read Full Report: http://www.transparencymarketresearch.com/nonalcoholic-steatohepatitis-market.html

The report states that the diagnosis and treatment of NASH presents a sizeable opportunity for companies in the pharmaceutical and biotech sector. A rise in the number of NAFLD cases (which could lead to NASH), increasing incidence of obesity, and changes in lifestyles of people worldwide will all eventually act as growth drivers for the global NASH market. This gives companies an opportunity to explore new avenues for growth in the global nonalcoholic steatohepatitis market. TMR analysts also state that in the long run, the growth of the NASH market will also be hinged on NASH being associated with morbid conditions such as insulin resistance and obesity. This indicates a massive unmet demand for drugs and therapeutic treatments for NASH, creating new revenue-generation areas for companies in the market.

The report also offers an overview of the competitive scenario prevailing in the global NASH market. To this end, the study profiles leading companies and reports their recent market developments. Among the players profiled in the report on the global NASH market are: AstraZeneca plc, Exalenz Bioscience Inc., Echosense SA, Galectin Therapeutics Inc., One Way Liver Genomics, Galmed Pharmaceuticals Ltd., Intercept Pharmaceuticals, Inc., GENFIT Corp, S.L, Perspectum Diagnostics, Matinas Biopharma Holdings, Inc. and Vital Therapies, Inc.

Get Free Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=7691

Given that NASH treatments still have much ground to cover, there is immense scope for novel therapies and formulations to be launched in the global global nonalcoholic steatohepatitis market. Thus, innovation will remain the cornerstone of growth for companies vying for a higher share of revenue in the global NASH market.

About Transparency Market Research (TMR)
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:
Mr. Sudip S
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/